Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity

18d ago

ESPR

PremiumPress Releases

Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024

24d ago

ESPR

PremiumPress Releases

Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference

1M ago

ESPR

PremiumPress Releases

Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24

1M ago

ESPR

PremiumPress Releases

U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

1M ago

ESPR

PremiumPress Releases

CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events

1M ago

ESPR

PremiumPress Releases

Esperion Reports Fourth Quarter and Full Year 2023 Financial Results

2M ago

ESPR

More ESPR News >

ESPR News on the Web

2024-04-23

Esperion to Report First Quarter 2024 Financial Results on May 7

Yahoo Finance

Neutral

2024-04-21

11 Best Low Price Pharma Stocks To Invest In

Yahoo Finance

Neutral

2024-04-10

Understanding Serge Belanger’s Buy Rating for Esperion (ESPR): A Critical Analysis

TipRanks News

Neutral

2024-04-07

Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity

Yahoo Finance

Bullish

2024-04-01

Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024

Yahoo Finance

Bullish

2024-03-28

Does Esperion Therapeutics Inc (ESPR) Have What it Takes to be in Your Portfolio Thursday?

Investors Observer

Neutral

2024-03-28

Why Is Esperion Therapeutics Up 2% Since Last Earnings Report?

Yahoo Finance

Neutral

2024-03-28

Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report?

Zacks

Neutral

News Score - Last 7 Days

Neutral

ESPR

Sector Average

Media Buzz

This Week2 articles

Weekly Average2 articles

News Sentiment

This Week50%

Sector Average58%

See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is ESPR’s Media Buzz Sentiment?

2 articles about ESPR were published this week. In an average week, 2 articles are published.

What is ESPR’s weekly average amount of articles?

In an average week, 2 articles about ESPR are published.

What is ESPR’s News Sentiment?

50% of articles about ESPR were positive this week, compared to its sector average of 58%.

Healthcare Stocks that are Trending in the News

DAWNDay One Biopharmaceuticals

IMVTImmunovant

RVVRevive Therapeutics

NVSNovartis

ISRGIntuitive Surgical

Showing the stocks with the most bullish news sentiment over the past week

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing